Thus, IL-6 inhibitors may help to reduce the severe inflammation associated with severe COVID-19 (Fig. 2).Tocilizumab, the first pharmacological anti-IL-6 receptor authorized for RA treatment, initiated two days before intensive care unit admission, was linked to a reduced chance of mortality, as shown in a large cohort analysis [140]. Here, IL6 is linked to rheumatoid arthritis.